亚甲基四氢叶酸还原酶 C677T 多态性可预测中国汉族人群接受基于吉西他滨的化疗治疗晚期非小细胞肺癌的反应和进展时间。
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
机构信息
Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
出版信息
J Zhejiang Univ Sci B. 2013 Mar;14(3):207-15. doi: 10.1631/jzus.B1200101.
Abstract
OBJECTIVE
The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
METHODS
A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods.
RESULTS
The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival.
CONCLUSIONS
Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.
摘要
目的
本研究旨在评估亚甲基四氢叶酸还原酶（MTHFR）C677T 切除修复交叉互补组 1（ERCC1）基因多态性与吉西他滨为基础的化疗在晚期非小细胞肺癌（NSCLC）中的临床疗效之间的关系。
方法
共 135 例未经手术的晚期 NSCLC 患者接受吉西他滨/铂类方案化疗。采用 TaqMan 方法检测 MTHFR C677T、ERCC1 C8092A 和 ERCC1 C118T 多态性。
结果
总缓解率为 28.9%。MTHFR CC 基因型患者的客观缓解率高于变异基因型（TT 或 CT）患者（41.2%比 19.1%，P=0.01）。MTHFR CC 基因型患者的中位无进展生存期（TTP）长于变异基因型患者（7.6 个月比 5.0 个月，P=0.003）。ERCC1 C118T 和 C8092A 多态性与反应和生存均无显著相关性。
结论
我们的数据表明，MTHFR C677T 多态性可能是吉西他滨/铂类治疗晚期 NSCLC 患者反应和 TTP 的预测标志物。
相似文献
1
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
J Zhejiang Univ Sci B. 2013 Mar;14(3):207-15. doi: 10.1631/jzus.B1200101.
2
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Clin Lung Cancer. 2004 May;5(6):360-5. doi: 10.3816/clc.2004.n.014.
3
Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer.
Med Sci Monit. 2017 Nov 29;23:5683-5689. doi: 10.12659/msm.904836.
4
Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.
Yonsei Med J. 2013 Nov;54(6):1384-93. doi: 10.3349/ymj.2013.54.6.1384.
5
Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Gene. 2013 Sep 10;526(2):265-74. doi: 10.1016/j.gene.2013.05.021. Epub 2013 May 30.
6
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
J Thorac Oncol. 2012 Jun;7(6):973-81. doi: 10.1097/JTO.0b013e31824fe98c.
7
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Tumour Biol. 2014 Nov;35(11):11159-70. doi: 10.1007/s13277-014-2427-6. Epub 2014 Aug 8.
8
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Clin Cancer Res. 2008 Mar 15;14(6):1797-803. doi: 10.1158/1078-0432.CCR-07-1364.
9
Allele and Genotype Frequencies of the Polymorphic Methylenetetrahydrofolate Reductase and Lung Cancer in ther Jordanian Population: a Case Control Study.
Asian Pac J Cancer Prev. 2015;16(8):3101-9. doi: 10.7314/apjcp.2015.16.8.3101.
10
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Oncol Rep. 2013 Nov;30(5):2385-98. doi: 10.3892/or.2013.2696. Epub 2013 Aug 26.
引用本文的文献
1
A Systematic Review of SNPs Screening for Platinum-Related Pharmacodynamics and Pharmacokinetics Genes in Non-Small Cell Lung Cancer for Precision Medicine.
Appl Clin Genet. 2025 Jun 27;18:93-112. doi: 10.2147/TACG.S518467. eCollection 2025.
2
Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Mol Biol Rep. 2024 Jan 13;51(1):102. doi: 10.1007/s11033-023-08915-2.
3
Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
PLoS One. 2023 May 4;18(5):e0284825. doi: 10.1371/journal.pone.0284825. eCollection 2023.
4
Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
Sci Rep. 2017 Jul 17;7(1):5593. doi: 10.1038/s41598-017-05642-0.
5
Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Oncotarget. 2016 Aug 23;7(34):55741-55756. doi: 10.18632/oncotarget.9688.
6
A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.
Dis Markers. 2016;2016:7643981. doi: 10.1155/2016/7643981. Epub 2016 Jan 21.
7
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Tumour Biol. 2014 Nov;35(11):11159-70. doi: 10.1007/s13277-014-2427-6. Epub 2014 Aug 8.
8
Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies.
Biomed Rep. 2014 Jul;2(4):452-462. doi: 10.3892/br.2014.282. Epub 2014 May 19.
9
The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Tumour Biol. 2014 Apr;35(4):2905-21. doi: 10.1007/s13277-013-1493-5. Epub 2013 Dec 13.
10
MTHFR C677T polymorphism contributes to the risk for gastric cancer.
Tumour Biol. 2014 Mar;35(3):2123-32. doi: 10.1007/s13277-013-1282-1.
本文引用的文献
1
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.
Cancer Chemother Pharmacol. 2012 Jun;69(6):1443-8. doi: 10.1007/s00280-012-1849-3. Epub 2012 Feb 28.
2
Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Pharmacogenomics J. 2012 Oct;12(5):379-85. doi: 10.1038/tpj.2011.25. Epub 2011 Jul 12.
3
Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1339-46. doi: 10.1007/s00280-011-1665-1. Epub 2011 May 18.
4
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
Lung Cancer. 2011 Jun;72(3):370-7. doi: 10.1016/j.lungcan.2010.10.011. Epub 2010 Nov 13.
5
[Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):337-41. doi: 10.3779/j.issn.1009-3419.2010.04.13.
6
Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Am J Clin Oncol. 2010 Oct;33(5):489-94. doi: 10.1097/COC.0b013e3181b9cedc.
7
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Br J Clin Pharmacol. 2010 Jan;69(1):58-66. doi: 10.1111/j.1365-2125.2009.03556.x.
8
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
J Clin Oncol. 2009 Dec 20;27(36):6251-66. doi: 10.1200/JCO.2009.23.5622. Epub 2009 Nov 16.
9
Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
Int J Colorectal Dis. 2010 Feb;25(2):141-51. doi: 10.1007/s00384-009-0779-y. Epub 2009 Aug 11.
10
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
J Clin Oncol. 2009 Jul 20;27(21):3540-6. doi: 10.1200/JCO.2008.20.8793. Epub 2009 May 26.
Zotero 插件